Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of AGN-151586 in Participants With Moderate to Severe Glabellar Lines

NCT04096326 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT04096326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04096326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of AGN-151586 in Participants With Moderate to Severe Glabellar Lines
Lead sponsor
Allergan
Phase
Phase 2
Overall status
Completed
Start date
September 26, 2019
Completion date
September 9, 2020
Enrollment
198 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar lines